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Body Composition Profiling in the UK Biobank Imaging Study
Jennifer Linge 1, Magnus Borga1,2,3, Janne West1,2,4, Theresa Tuthill5, Melissa R. Miller6, Alexandra Dumitriu6,
E. Louise Thomas7, Thobias Romu1,2,3, Patrik Tunon1, Jimmy D. Bell7, and Olof Dahlqvist Leinhard1,2,4
Objective: This study aimed to investigate the value of imaging-based multivariable body composition
profiling by describing its association with coronary heart disease (CHD), type 2 diabetes (T2D), and met-
abolic health on individual and population levels.
Methods: The first 6,021 participants scanned by UK Biobank were included. Body composition profiles
(BCPs) were calculated, including abdominal subcutaneous adipose tissue, visceral adipose tissue (VAT),
thigh muscle volume, liver fat, and muscle fat infiltration (MFI), determined using magnetic resonance
imaging. Associations between BCP and metabolic status were investigated using matching procedures
and multivariable statistical modeling.
Results: Matched control analysis showed that higher VAT and MFI were associated with CHD and T2D
(P< 0.001). Higher liver fat was associated with T2D (P<0.001) and lower liver fat with CHD (P<0.05),
matching on VAT. Multivariable modeling showed that lower VAT and MFI were associated with metabolic
health (P<0.001), and liver fat was nonsignificant. Associations remained significant adjusting for sex,
age, BMI, alcohol, smoking, and physical activity.
Conclusions: Body composition profiling enabled an intuitive visualization of body composition and
showed the complexity of associations between fat distribution and metabolic status, stressing the
importance of a multivariable approach. Different diseases were linked to different BCPs, which could not
be described by a single fat compartment alone.
Obesity (2018) 00, 00–00. doi:10.1002/oby.22210
Introduction
Anthropometric measures, such as BMI, are poor predictors of body
fat distribution and associated metabolic risk, particularly at an indi-
vidual level (1-3). Moving toward individualized medicine, specific
measures of body composition could greatly advance our under-
standing of obesity, metabolic health, aging, and chronic diseases.
Magnetic resonance imaging (MRI) is extensively used for body
composition analysis (2,4-7) and is accepted as the gold standard in
body composition research (4,8). Recently developed MRI techni-
ques allow for advanced body composition profiling and phenotyp-
ing using standardized acquisition protocols, enabling a comparison
of measurements across large-scale cohorts and between different
studies (7,9). The use of these techniques enables separation of fat
and muscle compartments from a single 6- to 10-minute MRI exam-
ination with a high success rate (7).
Ectopic fat accumulation in various compartments of the body is a
hallmark of metabolic syndrome and related comorbidities (10,11).
Increased visceral adipose tissue (VAT) is related to increased car-
diac risk (12-14,16), type 2 diabetes (T2D) (15,16), liver inflamma-
tion and fibrosis (17), and certain types of cancer (18,19). Increased
intramuscular adipose tissue, or muscle fat infiltration (MFI), has
been associated with reduced mobility (20) and increased risk for
T2D (21). Moreover, increased liver fat may lead to advanced fibro-
sis, cirrhosis, and hepatocellular carcinoma (22,23), and it is also
linked to the development of T2D (22,24).
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To understand the development of metabolic diseases, investigations
of the interplay between several different adipose tissue compart-
ments are needed. Although most adipose tissue compartments are
correlated with general adiposity and BMI, disease risks tend to be
related to specific patterns or balance in fat accumulation (2,12). To
further our understanding of the complex interplay between muscle
metabolism, adipose tissue accumulation, and ectopic fat, more
refined tools are needed.
The aims of this study were to investigate the value of multivariable
body composition profiling, by relating the individual body compo-
sition profile (BCP) to population scale data from the UK Biobank
imaging cohort (25), and to describe the specific associations with
diagnosed coronary heart disease (CHD), T2D, and metabolic health
by utilizing an intuitive multidimensional visualization.
Methods
Subjects
The first 6,021 participants from the UK Biobank imaging substudy were
included, with a mean age of 62.367.5 (44.6-78.3) years and a BMI of
26.764.4 (16.0-58.0) kg/m2. The UK Biobank is a population-based
study enrolled in 2006, following 502,682 participants, with the aim to
improve the prevention, diagnosis, and treatment of a wide range of seri-
ous and life-threatening illnesses. Baseline assessment gathered extensive
information via physical measurements, questionnaires, samples, and
consent to access medical records. Following baseline assessment,
100,000 participants are being recalled for an imaging study of the brain,
heart, bones, carotid arteries, and body composition, as well as a repeat of
the baseline assessment (26). This research has been conducted using the
UK Biobank resource, project ID 6569. The study was approved by the
North West Multicenter Research Ethics Committee in the United King-
dom. Written informed consent was obtained prior to study entry.
MRI scanning
The subjects were scanned in a Siemens MAGNETOM Aera 1.5-T MRI
scanner (Siemens Healthineers, Erlangen, Germany) using a 6-minute
dual-echo Dixon Vibe protocol, providing a water and fat separated volu-
metric data set covering neck to knees, and a single-slice multiecho Dixon
acquisition for proton density fat fraction (PDFF) assessment in the liver.
For body composition, acquired image data were analyzed for VAT,
abdominal subcutaneous adipose tissue (ASAT), thigh muscle volume,
MFI in the anterior thighs, and liver PDFF. Briefly, the image analysis
consisted of (1) image calibration, (2) fusion of image stacks, (3) image
segmentation, and (4) quantification of fat and muscle volumes (7,9,27-
29) and included manual quality control by an analysis engineer. Body
composition analyses were performed using AMRA Profiler Research
(AMRA Medical AB, Link€oping, Sweden). The online Supporting Infor-
mation provides detailed information of in vivo acquisitions and analysis.
Body composition profiling
A BCP was defined as a combination of variables that together
describe the fat and/or muscle distribution of an individual or group.
When applying statistical modeling, the following BCP variables
describing adipose tissue distribution throughout the body without
physically overlapping each other were used: VAT index (VATi), or
VAT normalized by height squared to compensate for subject size
(30); ASAT index (ASATi), or ASAT normalized by height squared;
liver PDFF; and MFI. When visualizing body composition, the six-
axis BCP plot was used (Figure 1).
Visualizing BCP
The variables used in the BCP plot jointly describe fat accumulation
and fat and muscle distribution, and they allow for a quick assess-
ment of body composition based on the shape in the BCP plot. Spe-
cifically, the visualization illustrates the balance between different
adipose tissue compartments and the distribution of fat, diffuse fat
infiltration, and muscles in the body. It comprises VATi; total
abdominal adipose tissue index (TAATi), which is the total abdomi-
nal fat (VAT1ASAT) normalized by height squared, a fat-specific
version of BMI; weight-to-muscle ratio (WMR), which is body
weight divided by thigh muscle volume, indicating the ability of
subjects to carry their weight; fat ratio (FR), which is the total
abdominal fat divided by total abdominal fat and thigh muscle vol-
ume, assessing the distribution between fat and muscle volume;
MFI; and liver PDFF.
The BCP plot displays multivariable data in a six-axis radar chart
(Figure 1). Because of the difference in magnitude and distribution
between the BCP variables, they were mapped using a logarithmic
sigmoid transfer function (Figure 2) with distribution-specific con-
stants to values between 0 (chart center) and 1 (end of spokes). The
same type of transfer function, with the median values of a meta-
bolic disease-free (MDF) group as references, was used for all varia-
bles. To align the distribution-specific constants and reference values
in the radar chart, and therefore level the visual response between
variables, they were mapped to fixed distances from the chart center.
The reference values were mapped to 0.15 for variables with only
ectopic fat (liver PDFF, VATi, and MFI) and to 0.6 for the remain-
ing variables, forming the shape of a star (Figure 1A). Changes in
variables on axes with only ectopic fat dominated the appearance of
the resulting BCP (i.e., highlighting the ectopic fat compartments).
An individual was visualized with a line (Figure 1B) and a group
with a shaded field covering the interquartile range (Figure 1C-1D).
Stratification of metabolic subgroups
Diagnosis information was gathered through inpatient electronic
health care records (downloaded November 2016, available from
1995-2015) and via touch screen questionnaires followed by inter-
views performed by trained nurses.
Metabolic disease free. To identify subjects asymptomatic of met-
abolic diseases, a list of conditions considered to be serious enough to
represent metabolically focused health concerns (e.g., cardiovascular
and metabolic diseases, severe chronic conditions, neurological diseases,
cancers) (Supporting Information Table S1), reviewed by an experi-
enced clinician, was used. Participants were considered MDF if they
did not report any of the listed diseases (UK Biobank field identifica-
tion numbers 20001 and 20002) (31) and if they did not have the Inter-
national Classification of Diseases, 10th Revision (ICD-10) codes map-
ping to strings similar to the listed diseases (supplementary file by
Neuraz et al. used for mapping) (32).
CHD.
• Cases—Data from the electronic health care records only were
used to identify subjects with diagnosed CHD. Subjects with ische-
mic heart disease or presence of aortocoronary bypass graft (ICD-10
codes I20-I25, Z951) were considered CHD cases.
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• Controls—CHD controls did not have any of the above ICD-10
codes. In addition, they had no self-reported history of heart attack,
angina, other heart and/or cardiac problems, or diabetes diagnosed
by a doctor. Supporting Information Table S2 lists fields used for
stratification. Statistical analyses excluded subjects not characterized
as CHD cases or controls (n5 1,384).
T2D.
• Cases—Subjects with diabetes diagnosed by a doctor and an age
of diagnosis of 30 years or older were considered T2D cases.
• Controls—Subjects with diabetes diagnosed by a doctor and an
age of diagnosis younger than 30 years, or with gestational diabe-
tes, were excluded from the T2D controls. Supporting Information
Table S3 lists fields used for stratification. Statistical analysis
excluded subjects not characterized as T2D cases or controls
(n5 38).
Matched controls. For CHD and T2D, two matched control
groups were stratified matched on (1) sex and age and (2) sex, age,
and BMI. Each control was chosen as the nearest neighbor with the
same sex in the euclidean space constructed by (1) age and (2) nor-
malized (standard score normalization) age and BMI.
Cases had controls selected by repeating the following: (1) exclude
controls with opposite sex, (2) choose the closest control, and (3)
remove that control from remaining controls.
Figure 1 Visualization examples of the body composition profile (BCP). (A) Median of a metabolic disease-free
(MDF) population (same in B-D); (B) an individual BCP (orange); (C) a group visualized as the field spanning the inter-
quartile range (green); (D) two groups visualized as fields spanning their interquartile ranges (green and pink); brown
areas represent the overlap between groups. FR, fat ratio; MFI, muscle fat infiltration; PDFF, proton density fat frac-
tion; TAATi, total abdominal adipose tissue index; VATi, visceral adipose tissue index; WMR, weight-to-muscle ratio.
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Acquisition and definition of covariates
Height was recorded using a Seca 240 height measure (Seca, Ham-
burg, Germany), and weight was recorded with a Tanita BC-418MA
body composition analyzer (Tanita Corp., Arlington Heights, Illinois).
Smoking status, alcohol intake, physical activity, and statin medica-
tion were derived using data from touch screen questionnaires and/or
interviews (see Supporting Information for further details).
Statistical analysis
Individual assessment. Two multivariable logistic regression
models were used to investigate each individual’s association to
CHD, T2D, and MDF, including (1) sex and age and (2) sex, age,
and BCP (VATi, ASATi, liver PDFF, and MFI). To adjust for the
sex and age dependence in the disease prevalence data, a sex-and-
age normalized predicted probability was calculated. Each predicted
probability, calculated using the log odds from the model outputs
including BCP, was divided by that from the model including only sex
and age. Subjects from three BMI intervals, 24 (23-25) (normal weight),
28 (27-29) (overweight), and 32 (31-33) (obesity), all approximately 65
years old, were used to exemplify.
Group assessment. The CHD and T2D subgroups were visual-
ized in BCP plots. The statistical significance of differences in the
BCP variables between cases and controls was tested using the non-
parametric Mann-Whitney U test (P< 0.05 significant).
Statistical modeling. Multivariable logistic regression models
were also used to investigate the association of CHD, T2D, and MDF
to BCP (VATi, liver PDFF, MFI, and ASATi), including potential
confounding effects of sex and age (Model MV), smoking status,
alcohol intake, and physical activity (Model MV1 lifestyle), and
BMI (Model MV1 lifestyle1BMI). Liver PDFF was Box-Cox trans-
formed (k520.51). All models were run for the whole cohort, males
and females separately, with and without statin treatment adjustment.
Post hoc analysis. For CHD, the group assessment was extended
by comparison with a control group matched on sex, age, and
VATi. Computations were performed using R version 3.4.0 (The R
Foundation, Vienna, Austria). The Supporting Information lists addi-
tional R packages.
Results
Descriptive characteristics
Table 1 summarizes the characteristics of all participants, males,
females, and MDF subjects. Among females, 85.2% had menopause
or had undergone a hysterectomy.
Statistical analysis
Individual assessment. Figure 3 exemplifies individual BCP
assessments with sex-and-age normalized predicted probabilities for
CHD, T2D, and MDF in bar plots. Females were used to exemplify.
Supporting Information Figure S1 shows the results for males. The
predicted probabilities for CHD and T2D did not covary, i.e., within
all BMI ranges, subjects exhibited different combinations of the fol-
lowing predicted probabilities for CHD and T2D: low-low, high-
low, low-high, and high-high. Among subjects with overweight and
Figure 2 Density and scaling of BCP variables. Left panels are the density plots for each BCP variable comparing MDF subjects (solid contour) with those
not characterized as MDF (dashed contour); right panels are the transfer functions from BCP variable values to their position on corresponding axes in the
BCP plot, including median values (solid line) and the interquartile ranges (shaded areas) of the MDF group as reference and the 5th and 95th percentile of
the whole cohort (dashed lines). BCP, body composition profile; MDF, metabolic disease free. [Color figure can be viewed at wileyonlinelibrary.com]
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obesity, there were those exhibiting lower predicted probability for
disease compared with subjects with normal weight.
Group assessment. CHD and T2D cases showed significantly
higher values for all BCP plot variables (P< 0.001) compared with all
controls (Figure 4; Table 2). Comparing CHD cases with sex-and-age
matched controls, all variables except liver PDFF had significantly
higher values (P< 0.001). Comparison with sex, age, and BMI matched
controls showed significantly higher values in VATi (P< 0.05) only.
Comparison with sex, age, and VATi matched controls (post hoc analy-
sis) showed significance in liver PDFF only. Liver PDFF was lower
among CHD cases (2.69% [1.64-7.39%] median, interquartile range)
compared with controls (3.64% [2.04-7.20%]; P< 0.05).
Comparing T2D cases with sex-and-age matched controls, all varia-
bles had significantly higher values (P< 0.001). Comparison with
sex, age, and BMI matched controls showed significantly higher val-
ues for WMR, VATi, liver PDFF, and MFI (P< 0.05). Differences
in FR and TAATi were nonsignificant.
Statistical modeling. Figure 5 presents multivariable logistic
regression results showing associations of CHD, T2D, and MDF
with BCP for the whole cohort as well as males and females sepa-
rately. CHD had a positive association to VATi when applying mul-
tivariable statistical modeling to the whole cohort (P< 0.001), males
only (P< 0.001), and females only (P5 0.013), adjusted for sex
(whole cohort) and age (Model MV). Associations remained signifi-
cant after adjustment for lifestyle factors (smoking status, alcohol
intake, and physical activity; Model MV1 lifestyle) and BMI
(Model MV1 lifestyle1BMI) and statin treatment. MFI was posi-
tively associated with CHD for the whole cohort (P5 0.018), when
adjusting for sex and age and when applying all adjustments (Mod-
els MV1 lifestyle and MV1 lifestyle1BMI), except for statin
treatment. In the females only model, MFI was significantly higher
when adjusting for age (P5 0.022) (Model MV). In the male model,
MFI was nonsignificant. Liver PDFF was negatively associated with
CHD for the whole cohort (P5 0.004) and in males (P< 0.001)
adjusting for sex (whole cohort) and age. Associations remained sig-
nificant applying all adjustments (Models MV1 lifestyle and
MV1 lifestyle1BMI), including statin treatment. The association
between liver PDFF and CHD in the female model was nonsignifi-
cant. ASATi was nonsignificant in all models.
T2D was associated with higher VATi, liver PDFF, and MFI adjust-
ing for sex (whole cohort) and age (all P< 0.01) (Model MV).
Associations remained significant after applying all adjustments
(Models MV1 lifestyle and MV1 lifestyle1BMI), including statin
treatment. ASATi was nonsignificant.
MDF was associated with lower VATi for the whole cohort
(P< 0.001), males only (P< 0.001), and females only (P5 0.013),
TABLE 1 Descriptive characteristics of overall participants, males, and females
Whole cohort Males Females Metabolic disease free
N subjects 6,021 2,864 3,157 1,996
Age, y 63.15 (56.47-68.15) 64.29 (57.44-68.74) 62.35 (55.84-67.50) 60.26 (53.72-66.09)
Sex, male/female 2,864/3,157 2,864/0 0/3,157 928/1,068
Coronary heart disease, % 3.9 5.8 2.3 0
Type 2 diabetes, % 4.6 6.5 3.0 0
Metabolic disease free, % 33.2 32.4 33.8 100
Weight, kg 75.00 (65.50-85.70) 82.80 (75.00-91.50) 67.40 (60.50-76.10) 72.90 (64.00-83.50)
BMI, kg/m2 26.14 (23.63-29.04) 26.75 (24.52-29.28) 25.38 (22.87-28.76) 25.36 (23.17-28.11)
Physical activity, MET-min/wk 3,519.75
(1,804.33-6,002.62)
3,817.97
(2,022.56-6,445.19)
3,222.00
(1,635.16-5,620.94)
3,766.25
(2,046.59-6,349.69)
Smoking status, never/previous/current 3,594/2,093/262 1,595/1,086/152 1,999/1,007/110 1,277/598/95
Alcohol intake, g/d 15.80 (6.75-27.92) 20.15 (10.53-35.73) 11.57 (5.27-21.06) 15.80 (7.90-27.71)
Statins medication, % 20.61 28.87 13.11 4.65
Visceral adipose tissue, L 3.32 (1.94-5.03) 4.62 (3.25-6.38) 2.33 (1.46-3.51) 2.78 (1.64-4.30)
Abdominal subcutaneous adipose tissue, L 6.44 (4.77-8.65) 5.50 (4.27-7.06) 7.50 (5.57-9.93) 5.94 (4.39-8.04)
Thigh muscle volume, L 9.87 (8.14-12.27) 12.39 (11.23-13.53) 8.23 (7.49-9.06) 9.94 (8.16-12.40)
Weight-to-muscle ratio, kg/L 7.43 (6.63-8.43) 6.68 (6.22-7.23) 8.25 (7.53-9.13) 7.18 (6.41-8.13)
Liver proton density fat fraction, % 2.34 (1.47-4.55) 2.87 (1.74-5.67) 1.96 (1.32-3.69) 2.04 (1.38-3.57)
Fat ratio, % 50.14 (42.24-57.76) 45.76 (38.89-51.62) 55.35 (47.35-61.74) 47.24 (39.49-55.04)
Visceral abdominal adipose tissue index, L/m2 1.17 (0.71-1.72) 1.52 (1.05-2.07) 0.89 (0.55-1.33) 0.99 (0.60-1.46)
Abdominal subcutaneous adipose
tissue index, L/m2
2.23 (1.63-3.14) 1.78 (1.38-2.29) 2.87 (2.10-3.78) 2.06 (1.47-2.90)
Total abdominal adipose tissue index, L/m2 3.57 (2.61-4.69) 3.38 (2.53-4.32) 3.82 (2.72-5.08) 3.18 (2.35-4.17)
Muscle fat infiltration, % 7.19 (6.18-8.42) 6.66 (5.73-7.77) 7.67 (6.66-8.88) 6.79 (5.79-7.86)
For continuous variables, median and interquartile range shown.
MET, metabolic equivalents.
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adjusting for sex (whole cohort) and age, and lower MFI (all
P< 0.02), adjusting for sex (whole cohort) and age (Model MV).
Liver PDFF was nonsignificant. Associations remained significant
after applying all adjustments (Models MV1 lifestyle and MV1 li-
festyle1BMI), including statin treatment. ASATi was significant in
the male model including BMI (P5 0.045).
Discussion
This study examined the effectiveness of multivariable, MRI-based
body composition profiling to further our understanding of metabolic
health. Investigating the associations between CHD and T2D and
each fat compartment separately (Table 2) showed positive
Figure 3 Body composition profiling of females from the UK Biobank imaging cohort. Each subject, approximately age 65, is presented with
a coronal slice from the MRI scan with VAT (red) and ASAT (blue) segmentations, the BCP values with corresponding six-axes plots, and bar
plots showing sex-and-age normalized predicted probabilities. BCP, body composition profile; CHD, coronary heart disease; FR, fat ratio;
MDF, metabolic disease free; MFI, muscle fat infiltration; ASAT, abdominal subcutaneous adipose tissue; PDFF, proton density fat fraction;
T2D, type 2 diabetes; TAATi, total abdominal adipose tissue index; VATi, visceral adipose tissue index; WMR, weight-to-muscle ratio.
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associations with most of the fat compartments. Matching on BMI
left only VATi with a significant association to CHD, while
matching on VATi instead of BMI showed a significant negative
association to liver PDFF. This result was also reflected in the
whole cohort and among males when applying statistical modeling
including multiple fat compartments (Figure 5). Low ectopic fat,
especially VATi and MFI, was positively associated with meta-
bolic health, and higher values were found among subjects with
metabolic diseases (Table 2; Figure 4 and Figure 5), while liver
PDFF had no significant association. The modeling results remained
significant after adjusting for sex, age, lifestyle factors, BMI, and sta-
tin treatment. The individual BCP assessment showed that within the
same sex, age, and BMI group (normal weight, overweight, and obe-
sity), a variety of individual BCPs were found, exhibiting different
combinations of predicted disease probabilities (Figure 3). Taken
together, these findings stress the importance of a multivariable
approach investigating associations between fat distribution and meta-
bolic diseases. Different diseases were linked to different BCPs, or
imbalances in fat accumulation, which could not be described by sex,
age, lifestyle, or generalized adiposity or by investigating a single fat
compartment alone.
Context of current literature
VATi was identified as a key variable in understanding metabolic
diseases. For CHD, this is concurrent with prospective findings
from, for example, the Dallas Heart Study (2) and Framingham
Heart Study (12), showing associations between elevated VAT and
increased cardiovascular risk factors and incidence of cardiovascular
events. For T2D, our results agree with those from the Cooperative
Health Research in the Augsburg Region (KORA) MRI study (24),
in which significantly higher VAT and liver fat were found among
diabetics and prediabetics without previous cardiovascular problems.
These differences remained significant after correction for sex, age,
systolic blood pressure, smoking status, high-density lipoprotein and
low-density lipoprotein cholesterol levels, and triglyceride levels.
The results associating liver PDFF to T2D are well aligned with pre-
viously observed associations to the development of diabetes (22).
However, for liver fat and CHD, the picture is more complex. There
are many studies that have linked hepatic steatosis to cardiovascular
disease (33-35) as well as recent studies that have reported elevated
liver fat as not having a significant association to CHD after BMI
adjustment. However, there are few studies that have investigated
liver fat as one among multiple body composition biomarkers
describing fat accumulation. Another is the Dallas Heart Study,
showing the importance of VAT and no association of cardiovascu-
lar events to liver fat after correction for BMI or VAT (2). Impor-
tant differences comparing this study and the present is that it only
included subjects with obesity and, possibly, too few cases to reveal
multivariable associations. A recent large study investigating long-
term outcomes in patients with biopsy-proven nonalcoholic fatty
liver disease (NAFLD) showed no significant difference in cardio-
vascular death comparing NAFLD cases with controls (36). How-
ever, this study did not include other fat compartments, leaving mul-
tivariable associations unknown.
Lower liver PDFF among those who have experienced a cardiac
event, as compared with controls, might be caused by subsequent
disease treatment, or it could be an indication that a phenotype
exists exhibiting a body composition with skewed fat accumulation
that is associated with diagnosed CHD or common CHD comorbid-
ities, such as chronic liver disease. The nonsignificant association
between liver PDFF and CHD observed in females might be because
Figure 4 Body composition profiling of coronary heart disease and type 2 diabetes. Pink and green fields represent
the interquartile ranges of cases and controls, respectively, brown areas the overlap between groups, and dashed
blue lines the median of a metabolic disease-free group as reference. FR, fat ratio; PDFF, proton density fat fraction;
MFI, muscle fat infiltration; T2D, type 2 diabetes; TAATi, total abdominal adipose tissue index; VATi, visceral adipose
tissue index; WMR, weight-to-muscle ratio.
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TABLE 2 Descriptive statistics and results on coronary heart disease and type 2 diabetes
Disease group All controls Matched controls
Matched
controls1BMI
Coronary heart disease
N subjects 237 4,400 237 237
Age, y 67.61 (62.78-71.22) 61.56 (55.14-67.07) 67.61 (62.79-71.23) 67.50 (63.09-71.14)
Sex, male/female 165/72 1,838/2,562 165/72 165/72
Weight, kg 80.80 (71.20-90.85) 73.00 (64.00-83.80) 78.00 (69.60-86.10) a 81.30 (72.00-91.30)
BMI, kg/m2 27.52 (24.98-30.53) 25.64 (23.25-28.48) 26.32 (23.83-28.85) b 27.45 (24.97-30.47)
Physical activity, MET-min/wk 3,498.62
(1,520.19-5,901.56)
3,579.75
(1,878.50-6,101.81)
3,819.75
(2,065.75-6,382.50)
3,449.19
(1,872.94-6,715.00)
c
Smoking status, never/previous/current 115/100/16 2,762/1,439/188 142/87/7 d 126/106/4
Alcohol intake, g/d 16.14 (5.96-29.30) 15.80 (7.10-27.36) 18.77 (9.04-31.94) c 18.43 (8.93-32.41)
Statins medication, % 81.013 0.5 0.844 e 0.422 e
Visceral adipose tissue, L 4.71 (2.95-6.66) 2.94 (1.73-4.41) 3.89 (2.45-5.56) b 4.32 (2.72-6.16)
Abdominal subcutaneous adipose tissue, L 6.57 (4.85-8.89) 6.32 (4.64-8.54) 5.98 (4.41-8.02) c 6.50 (4.77-9.46)
Thigh muscle volume, L 11.04 (8.93-12.57) 9.47 (8.02-12.03) 11.27 (9.09-12.76) 11.48 (9.00-13.00)
Weight-to-muscle ratio, kg/L 7.51 (6.68-8.49) 7.43 (6.59-8.41) 7.04 (6.43-7.91) a 7.21 (6.52-8.42)
Liver proton density fat fraction, % 2.69 (1.64-7.39) 2.15 (1.40-3.95) 2.53 (1.55-5.08) 2.89 (1.77-5.84)
Fat ratio, % 52.32 (44.84-59.37) 49.34 (41.24-57.18) 47.88 (40.70-55.71) b 50.03 (41.68-59.29)
Visceral abdominal adipose tissue index, L/m2 1.72 (1.08-2.24) 1.05 (0.63-1.55) 1.29 (0.83-1.85) b 1.48 (0.97-2.06) c
Abdominal subcutaneous adipose
tissue index, L/m2
2.21 (1.70-3.07) 2.21 (1.59-3.12) 1.99 (1.47-2.92) a 2.16 (1.55-3.30)
Total abdominal adipose tissue index, L/m2 4.14 (3.01-5.33) 3.39 (2.49-4.54) 3.36 (2.60-4.68) b 3.89 (2.85-5.23)
Muscle fat infiltration, % 7.82 (6.55-9.33) 7.07 (6.08-8.21) 7.32 (6.27-8.16) b 7.49 (6.31-8.89)
Type 2 diabetes
N subjects 279 5,704 279 279
Age, y 65.57 (60.99-70.44) 62.99 (56.34-68.05) 65.57 (60.99-70.43) 65.75 (61.13-70.49)
Sex, male/female 183/96 2,669/3,035 183/96 183/96
Weight, kg 85.55 (77.12-98.92) 74.40 (65.20-85.10) 77.90 (68.62-88.75) b 87.50 (75.55-98.40)
BMI, kg/m2 29.51 (26.54-33.44) 25.99 (23.54-28.85) 26.56 (24.15-28.91) b 29.48 (26.59-33.38)
Physical activity, MET-min/wk 2,475.75
(1,102.81-4,597.31)
3,543.75
(1,853.59-6,061.50)
3,790.88
(1,940.23-5,851.69)
a 3,097.44
(1,629.00-5,768.56)
Smoking status, never/previous/current 141/123/12 3,435/1,954/248 164/98/13 148/120/9
Alcohol intake, g/d 10.98 (2.63-23.35) 15.80 (7.20-28.40) 16.14 (7.90-30.80) b 17.04 (7.90-35.89) b
Statins medication, % 69.176 18.145 25.806 e 28.674 e
Visceral adipose tissue, L 5.90 (3.95-7.72) 3.24 (1.91-4.88) 3.68 (2.28-5.42) b 5.20 (3.62-7.19) c
Abdominal subcutaneous adipose tissue, L 7.75 (5.68-10.54) 6.38 (4.73-8.54) 6.05 (4.38-8.25) b 7.58 (5.64-10.87)
Thigh muscle volume, L 10.86 (9.15-12.66) 9.81 (8.11-12.24) 11.21 (8.55-12.96) 11.51 (9.31-13.37) c
Weight-to-muscle ratio, kg/L 7.81 (7.04-8.94) 7.40 (6.62-8.41) 7.13 (6.44-8.03) b 7.56 (6.74-8.95) c
Liver proton density fat fraction, % 6.51 (2.69-12.82) 2.29 (1.46-4.28) 2.43 (1.61-4.88) b 3.70 (2.09-7.53) b
Fat ratio, % 56.14 (48.61-63.37) 49.82 (41.93-57.42) 49.21 (40.37-55.73) b 53.68 (46.41-62.53)
Visceral abdominal adipose tissue index, L/m2 2.04 (1.45-2.60) 1.14 (0.69-1.67) 1.29 (0.79-1.87) b 1.78 (1.27-2.37) a
Abdominal subcutaneous adipose
tissue index, L/m2
2.70 (1.87-3.72) 2.21 (1.62-3.11) 2.01 (1.45-2.86) b 2.60 (1.87-3.90)
Total abdominal adipose tissue index, L/m2 4.82 (3.76-6.32) 3.50 (2.59-4.62) 3.41 (2.57-4.50) b 4.57 (3.36-6.03)
Muscle fat infiltration, % 8.35 (6.96-9.87) 7.15 (6.15-8.35) 7.16 (6.10-8.38) b 7.75 (6.49-9.24) a
For continuous variables, median and interquartile range shown.
Matched controls are sex-and-age matched; matched controls1BMI are additionally matched on BMI.
aP< 0.01
bP< 0.001.
cP< 0.05 (two-sample t test).
dP< 0.05.
eP< 0.001 (Mann-Whitney U test).
MET, metabolic equivalents.
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of the lower prevalence of CHD among females, or that females
rarely exhibit the skewness in fat accumulation driving the negative
association between liver PDFF and CHD for the males. The observed
finding of liver PDFF being negatively associated with CHD was not
a direct effect of statin treatment. Prospective data can demonstrate
potential causality and predictive value of this finding.
Associations of MFI to metabolic risk factors have previously been
reported from the Framingham Heart Study (37). MFI has also been
reported to be associated with insulin resistance in obesity and T2D
(21). Our study showed a negative association between MFI and
MDF and a positive association to T2D. However, associations
between CHD and MFI were different in the sex-stratified analyses;
they were not significant for males and were significant, or border-
line significant, for females depending on correction factors.
Although the Framingham Heart Study (37) did adjust for VAT, the
approach of measuring MFI was not the same.
The individual BCP assessment (Figure 3) showed subjects with obesity
with lower disease probability compared with subjects with normal
weight, adding to the literature on healthy obesity (38-40). It was further
strengthened by the comparison between the subject with normal weight
with inflated BCP (Figure 3, top right) and the subject with obesity and a
more star-shaped BCP (Figure 3, bottom left). This comparison yields a
predicted probability for CHD and T2D with a factor 2 higher for the sub-
ject with normal weight and a factor 0.5 lower for MDF. That BMI has
Figure 5 Results from the multivariable statistical modeling of coronary heart disease, type 2 diabetes, and metabolic disease free. Odds ratios and
associated confidence intervals are shown with values and in forest plots. Black boxes indicate odds ratio value, horizontal lines the width of the
confidence interval, and the vertical dashed line the line of null effect. Arrows are shown where confidence intervals are exceeding axis limits. MV
model was adjusted for sex (whole cohort model only) and age. MV1 lifestyle was additionally adjusted for smoking status, alcohol intake, and phys-
ical activity. MV1 lifestyle1BMI was additionally adjusted for BMI. *Liver PDFF normalized using Box-Cox transform. ASATi, abdominal adipose tis-
sue index; CHD, coronary heart disease; CI, confidence interval; PDFF, proton density fat fraction; MDF, metabolic disease free; MFI, muscle fat
infiltration; OR, odds ratio; T2D, type 2 diabetes; VATi, visceral adipose tissue index.
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limitations in describing the individual is no longer a controversial state-
ment, and the existence of body compositions in subjects with high BMI
that are not disadvantageous from a health perspective has become more
accepted in current literature. However, the results from the individual
assessment yield a much more complex picture. Within all BMI classes, a
range of BCPs were found, some of which associated with MDF, others
with only CHD, only T2D, or those exhibiting comorbid disease associa-
tion. Individuals exhibiting high predicted probability for MDF (Figure 3,
first column) had BCPs more similar to the MDF group, represented by
the reference star. Individuals exhibiting high predicted probability for
CHD but low for T2D (Figure 3, second column) seemed to be character-
ized by high VATi and MFI but low liver PDFF. Individuals exhibiting
high predicted probability for T2D but low for CHD (Figure 3, third col-
umn) seemed to be characterized by high VATi and liver PDFF but low
MFI. Finally, individuals exhibiting comorbid disease association (Figure
3, fourth column) were characterized by high VATi, liver PDFF, and
MFI. Although these subjects are among the extremes on the spectrum of
combined predicted probabilities for CHD and T2D (i.e., low-low, high-
low, low-high, high-high), they exemplify the diversity in disease associa-
tions to multivariable body composition. This emphasizes the importance
of centering the analyses around the individuals, something rarely, if ever,
seen in the body composition literature.
Implications
This study showed the complexity in investigating disease associa-
tions to fat distribution and the importance of a multivariable
approach. With the identification of specific fat distributions associ-
ated with different diseases, more targeted and effective disease
treatments could be developed. Furthermore, a multivariable descrip-
tion of an individual’s body composition, attained from a single
examination, enables a more standardized and detailed description
of a patient’s metabolic disease status. By combining multivariable
body composition analysis with already measured biomarkers, there
is potential for highly individualized intervention plans.
Body composition profiling and visualization allowed for a quick and
simultaneous assessment of an individual’s or group’s fat accumula-
tion pattern, fat and muscle distribution, and balance between adipose
tissue compartments. The visualization introduces the possibility to
easily distinguish between different phenotypes in a multivariable
space. The star-shaped reference effectively shapes the BCP to high-
light the ectopic fat compartments, and a quick assessment, based on
current knowledge, of an individual’s risk profile can be made.
Our study makes significant advances to current literature by pre-
senting normative values of standardized body composition parame-
ters for metabolic health and disease (CHD and T2D) (Table 1 and
Table 2). This brings context of high importance to future studies
investigating body composition and metabolic disease.
The broad use of MRI to assess body composition has thus far not
been possible because of limitations in cost and access. Sources of
cost are, for example, the scanning time and laborious manual seg-
mentation of anatomical regions. In UK Biobank, a 6-minute protocol
was implemented for the complete body composition assessment, and
the combination with advanced image analysis techniques enabled
automatic segmentations of anatomical regions and extraction of bio-
marker values. Today, this is a solution available also outside the
image processing research community. The short acquisition protocol
and automated image analysis enable cost-effective assessment of
patients with suspected metabolic-related diseases, such as NAFLD,
chronic liver disease, or cardiovascular disease. In particular, this
technique can be easily added to provide further metabolic disease
profiling of such patients that are already examined using MRI.
Strengths and limitations
This study utilized measurements with high reproducibility, accu-
racy, and precision describing fat distribution gathered on a large
number of well-characterized subjects. The technique has been vali-
dated on many different MRI scanners, and the standardization of
measures allows comparisons across and between large cohorts.
Simultaneous inclusion of several body composition measures
strengthened the investigation of disease associations to adipose tis-
sue distribution. Furthermore, in terms of disease information, we
benefitted from the integration of self-reported and diagnosis data
from electronic health care records.
There are some limitations. First, this study was based on cross-sectional
data, and medications taken into account included only statins and not
the time on medication. This leaves the causality and predictive power of
the BCP unknown. Future analyses should focus on additional medica-
tions that may affect liver fat or adiposity. Second, self-reported data
were used to control for confounding effects and in disease definitions.
Future availability of biochemical assays and primary care data enables a
more detailed investigation of the metabolic syndrome. Thirdly, there is
evidence of UK Biobank exhibiting a “healthy volunteer” selection bias
(41). However, conclusions on associations between exposures and
health outcomes are generalizable to the wider population because of the
large sample size and heterogeneity of exposure measures (41). Also, the
bias was partly amended by correcting for general adiposity and lifestyle
factors. When more subjects have been scanned, further investigations
can be made, including other ethnicities, age ranges, and sociodemo-
graphic factors. Lastly, our study investigated the associations between
multivariable body composition and metabolic diseases, showing associa-
tions mainly to VATi, MFI, and liver PDFF. Investigating other areas of
disease may instead reveal the importance of other variables, including
lean muscle volume, total fat, and weight, WMR, FR, ASATi, and
TAATi.
Conclusion
Body composition profiling enabled an intuitive visualization of body
composition and showed the complexity of associations between fat
distribution and different metabolic diseases on both population and
individual levels, stressing the importance of a multivariable
approach. The analyses showed unique associations to diagnosed
CHD, T2D, and MDF. VATi and MFI were negatively associated
with MDF, and higher values were observed in CHD and T2D. The
associations of liver fat were ambiguous; they were negative with
CHD, positive with T2D, and nonsignificant with MDF. This could
not be described by sex, age, lifestyle, or generalized adiposity or by
investigating a single fat compartment alone. Altogether, multivari-
able body composition profiling showed the potential to improve the
description of the interplay between different adipose tissue compart-
ments, ectopic fat accumulation, and metabolic disease profiles.O
VC 2018 The Authors. Obesity published by Wiley Periodicals, Inc. on
behalf of The Obesity Society (TOS).
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